Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021

Jefferson M Jones; Jean D Opsomer; Mars Stone; Tina Benoit; Robyn A Ferg; Susan L Stramer; Michael P Busch

doi:10.1001/jama.2022.9745

Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021

JAMA. 2022 Jul 19;328(3):298-301. doi: 10.1001/jama.2022.9745.

Authors

Jefferson M Jones¹, Jean D Opsomer², Mars Stone³, Tina Benoit¹, Robyn A Ferg², Susan L Stramer⁴, Michael P Busch³

Affiliations

¹ COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
² Westat, Rockville, Maryland.
³ Vitalant Research Institute, San Francisco, California.
⁴ Scientific Affairs, American Red Cross, Gaithersburg, Maryland.

Abstract

This cross-sectional study examines monthly blood donations from individuals aged 16 years and older to estimate the population with antibodies to SARS-CoV-2 from infection or vaccination.

MeSH terms

Antibodies, Viral*
Blood Donors* / statistics & numerical data
COVID-19 Vaccines*
COVID-19* / epidemiology
COVID-19* / prevention & control
Humans
SARS-CoV-2
Seroepidemiologic Studies*
United States
Vaccines

Substances

Antibodies, Viral
COVID-19 Vaccines
Vaccines